⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495225 | 0.78 | CYP3A4 (0.55) | — | |
| SCHEMBL272745 | 0.76 | — | — | |
| SCHEMBL6609419 | 0.76 | — | — | |
| SCHEMBL154558 | 0.74 | — | — | |
| SCHEMBL7940321 | 0.74 | — | — | |
| Bromide SCHEMBL9249645 | 0.74 | CYP3A4 (0.50) | — | |
| SCHEMBL11549923 | 0.74 | — | — | |
| SCHEMBL1024496 | 0.74 | — | — | |
| SCHEMBL6631533 | 0.74 | — | — | |
| SCHEMBL8051976 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-08-19 | — | — | US | disclosed |
| CN-112961149-A | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-06-10 | — | — | US | disclosed |
| EP-3180335-B1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-107074841-B | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10556893-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10414760-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180334455-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2018-11-22 | — | — | US | disclosed |
| WO-2002079176-A1 | PROCESS FOR 2,4-DISUBSTITUTED-1,3,4-OXADIAZOLINE-5-THIONE AND 5-ONE COMPOUNDS | DOW AGROSCIENCES LLC (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002072559-A1 | PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | disclosed |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | MULVIHILL MARK JOSEPH (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055082-A2 | INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |